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TARGETING PH DOMAIN PROTEINS FOR 
CANCER THERAPY 
By Zhi Tan, M.D. 
Advisor: Shuxing Zhang, Ph.D. 
Abstract 
Targeted therapy has been one of the most promising treatment options for cancer during the past 
decade. Discoveries of potent and selective small molecule inhibitors are critical to new and 
promising targeted therapy. Pleckstrin Homology (PH) domain proteins are one of the biggest 
protein families in human proteome. However, no drugs have been achieved to the late 
development stages, let alone getting to the market. Thus, a deeper understanding about this protein 
family is required and there is an urgent need to develop novel small molecule compounds 
targeting these proteins.  
 
Studies of PH domains began around two decades ago and a lot of efforts have been focused on 
their structures and functions. However, not much is known about their role in cancers, except a 
few proteins such as AKT. In order to delineate the roles of PH domain proteins in cancers, we 
performed a comprehensive analysis of 313 PH domain proteins using 13 types of most common 
cancers in TCGA. From this analysis, we identified the most frequently upregulated and mutated 
PH domain proteins. Interestingly, we found Tiam1, a guanine nucleotide exchange factor (GEF) 
specific for Rac1 activation, was overexpressed in several cancers, particularly neuroendocrine 
prostate cancer.  
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Targeting PH domain proteins remains to be a significant challenge for multiple reasons. First, the 
binding pockets of most PH domain proteins are unknown due to lacking of PH-PIPs complex 
crystal structures. Second, these binding pockets are positively charged, which makes it really 
difficult to design small molecule inhibitors targeting these sites. In order to address these issues, 
we performed structural sequence alignment of available PH domain structures to identify 
conserved residues. Also, ensemble docking was performed in order to address the flexibility of 
the proteins. Through these efforts, we identified two scaffolds as Tiam1 small molecule inhibitors. 
These inhibitors showed binding affinity to the PH domain using surface plasmon resonance (SPR) 
assay and inhibition of Rac1 activation in prostate cancer cells. Also, these compounds inhibited 
prostate cancer cell proliferation and migration in vitro.  
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Chapter 1: Introduction 
1.1 PH domain as a drug target 
PH domain was first noted in pleckstrin, which contains two regions with high sequence 
similarity [1, 2]. As one of the most common protein domains in the human proteome, PH 
domains have very conserved secondary structures: seven beta sheets and one alpha helix at 
the C terminus, although with relatively low sequence identity. This protein domain 
containing about 120 amino acids is involved in intracellular signaling or serve as critical 
constituents of the cytoskeleton.  
 
One of the most important features of these proteins is that they bind to phosphatidylinositol 
lipids (such as phosphatidylinositol (4, 5)-bisphosphate and phosphatidylinositol (3,4,5)-
trisphosphate) and recruit proteins to the membranes of different cellular organelles. PIs 
consist of a water-soluble Myo-inositol head group linked by a glycerol moiety to two 
different fatty acid chains, usually a saturated C18 residue in the 1-position and a tetra-
unsaturated C20 residue in the 2-position [3]. Unphosphorylated phosphatidylinositols 
(PtdIns), usually synthesized in the endoplasmic reticulum, are transported to other 
membranes via PtdIns transfer protein [4, 5]. PIs bind to different cell membranes via two 
lipid tails. They also directly interact with proteins and regulate their functions via the water-
soluble inositol head group.  
 
The first type of PH domains bind to cytoplasmic membrane via PI(4,5)P2. Phospholipase C-
delta (PLC-δ) was the first PH domain protein that demonstrated the binding specificity to 
PI(4,5)P2 [6, 7]. Such interactions were found to be required in the recruitment of PH domain 
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proteins to the cytoplasmic membrane using green fluorescent protein (GFP) label [8, 9]. 
Later, PH domains binding to PI(3,4,5)P3 and PI(3,4)P2 were also found to be recruited to 
cytoplasmic membranes [10, 11] For example, AKT PH domain recognizes PI(3,4,5)P3 and 
PI(3,4)P2, but does not bind to PI(4,5)P2 [10, 12]. AKT will be recruited to the cytoplasmic 
membrane with the presence of these PIs. Other PH domain proteins that recognize PI3K 
products include BTK and GRP1. In contrast to these PIPs, the binding specificity to PI3P, 
PI5P and PI(3,5)P2 is far less well studied. The C-terminal TAPP1 PH domain may bind to 
these monophosphate PIPs, but shows relatively weak binding affinities [13]. Interestingly, 
binding of PI4P has been reported to specifically target the Golgi apparatus [14], although 
such binding alone may be not strong enough to drive the targeting and require assistance of 
other proteins like Arf1p [15]. OSBP and FAPP1 PH domains are examples of proteins 
targeting Golgi apparatus. Also, PH domains are known to mediate signaling transduction 
through protein-protein interactions [16]. In summary, PH domain proteins are implicated in 
multiple signaling pathways and they are potentially important targets for drug discovery.   
 
1.2 PH domain proteins in cancer 
Membrane recruitment has been noticed to be related to carcinogenesis. One of the best 
studied is the PIP3 signaling [17]. Through phosphorylation of PI (4, 5)P2 by the 
phosphatidylinositol-3-kinase (PI3K), PIP3 is accumulated in the cytoplasmic membrane and 
recruits PIP3 specific binding PH domain proteins such as AKT and PDK1 to the cell 
membrane [18, 19]. The concentration of PIP3 is upregulated by oncogenes like Ras and 
degraded by PTEN, which dephosphorylates PIP3 to PI(4,5)P2 [20, 21]. Mutations in the PH 
domain was first systematically reported in 2005 [22]. Carpten et al. identified E17K 
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mutation, which was located in the PIP3 binding pocket of the AKT PH domain in 9 out of 
162 cancer patients. This mutation increased the PIP3 binding affinity through replacing a 
negatively charged residue to a basic residue. Moreover, it was also observed that this 
mutation decreased the sensitivity to allosteric kinase inhibitors. Later, more and more driver 
mutations were reported in the PIP3 signaling pathways such as the RAS-PI3K-AKT axis 
[23]. For example, a mutation in the PDK1 PH domain causes inhibition of AKT and insulin 
resistance [24].  
 
1.3 Current situation of developing small molecule inhibitors targeting PH domains 
The initial interest of developing small molecule inhibitors of PH domains was to develop safe 
and potent AKT inhibitors. Although being one of the most critical oncogenes in the human 
genome, safe and selective AKT drugs have not been developed although intensively studied. 
Then researchers switched their interest to see if they can find small molecule inhibitors that bind 
to AKT PH domain. Initially, lipid-based derivatives were synthesized to mimic PI analogs [25-
27]. However, scientists quickly realized that these compounds had poor solubility and 
pharmacokinetics, although they showed some effect in cells [28]. After that, researchers 
recognized that novel chemical scaffolds were required to develop small molecule inhibitors 
targeting these domains. Mahadevan et.al. identified compounds that selectively bind to AKT PH 
domain [29]. In 2010, Miao et.al. identified two compounds that actively bind to AKT with Kd 
≈43.2 μM through screening of 50,000 compounds. Recently, another scaffold was reported to 
inhibit AKT PH domain with KD = 3.08 ± 0.49 μmol/L [30]. Also, several compounds targeting 
PH domains other than AKT were reported [31]. The activity of all these compounds are in 
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micromolar range and thus still far away from clinical use. As a result, there is an urgent need to 
discover more potent inhibitors to target these domains.  
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Chapter 2: Genomics, structural and PIPs binding specificity analysis of PH domain 
proteins 
2.1 Introduction 
Although it has been known that several PH domain proteins are involved in cancer mechanisms, 
lots of information about other PH domain proteins are still elusive such as the total number of 
PH domain proteins in the human proteome, frequency, and types of the genetic alterations of 
these proteins in cancer patients, and PIPs binding specificity.  
 
Herein, we extracted all proteins with annotations as PH domain proteins from the InterPro 
database and Uniprot website, which generated 313 PH domain proteins in total. Then we 
downloaded the expression level and mutation data of 13 types of most common cancer in The 
Cancer Genome Atlas (TCGA) dataset to explore the genetic changes of these 313 proteins. 
KEGG pathway analysis was performed to analyze which pathways these genes are significantly 
overrepresented. Clustering analysis was performed to identify the expression pattern of these 
genes across 13 types of cancers. Somatic mutation analysis of the 313 genes was performed to 
identify most frequently mutated PH domain genes in different types of cancers. Especially, 
mutations within PH domains were extracted and discussed separately.  
 
Then all the PH domain proteins in the PDB database were downloaded to perform structural 
multiple sequence alignment to identify the recognition pattern of the PIPs binding specificity. 
Also, all PH domain proteins annotated in the TCGA database were also aligned to identify 
conserved residues of PIPs binding.  
 
6 
 
Due to the limitation of the amount of data related to PH-PIPs binding affinity, we downloaded 
all abstracts published on PubMed to extract all PH-PIPs binding information to build a model to 
predict the binding specificity of all PH domain proteins using the convolutional neural network. 
A database with the PH domain protein information and PIPs binding specificity was generated 
and made available to the public online.  
  
2.2 Methods and materials 
2.2.1 KEGG pathway analysis of PH domain genes 
Although numerous studies about PH domain have been reported, the number of PH domain 
proteins is inconclusive in human proteome due to their diverse and integrative nature. We 
extracted all proteins annotated as PH domains in the InterPro web server [32]. Then duplicate 
proteins were removed based on their Gene IDs. As a result, a total of 313 PH domain proteins 
and their gene IDs were retrieved (Table 2.1). Some of the proteins have not been reviewed by 
the UniProt consortium [33]. However, these proteins were still kept in our list because they 
were annotated to contain PH domains and they comprised only a small part of the whole protein 
list. Then we examined the distribution of these PH domain genes within KEGG Pathways. The 
gene list was uploaded to the DAVID web server and converted to official gene symbols. Also, 
an overrepresentation test of these proteins among KEGG pathway was performed.   
 
2.2.2 Somatic mutation analysis 
We obtained the somatic mutation data from TCGA Pan-cancer effort on 
https://www.synapse.org. To decrease the noise from passenger mutations, samples with more 
than 500 somatic mutations (hypermutators) were removed from our study. Samples with no 
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somatic mutations were removed as well, resulting in mutations from 1,511 tumors for the 
following clustering analysis. Only non-silent somatic mutations were included in the analysis. 
SomInaClust[34] was used to identify genes with mutation patterns which resemble either those 
found in oncogene or tumor suppressor gene at a q value of 0.1. Hotspot mutation was defined as 
in-frame or missense mutations at the same amino acid in more than two samples.     
 
2.2.3 Unsupervised clustering  
Expression levels of 313 PH domain genes across the 3,281 tumors were collected. Matrix 
(sample × gene) with mutation status and gene expression levels were constructed and passed to 
perform complete-linkage hierarchical clustering using R function ‘hclust’. Also, heatmaps with 
dendrograms were visualized using R function “heatmap.2” in the gplots package.    
 
2.2.4 Curation of PH domain proteins from PDB 
Crystal structures of PH domain proteins were downloaded from the PDB website and duplicate 
structures were removed. In total, 34 unique structures were used to build a maximum likelihood 
(ML) tree based on their structure-based sequence alignment.  
 
2.2.5 Structural sequence alignment and weblogo generation 
All PH-PIPs structure complexes available in PDB (Table 5.1) were collected to perform multiple 
sequence alignment based on their secondary structures using STRAP [35].  The output of the 
alignment was then used to generate the signatures of conserved residues involved in PIP binding 
using Weblogo web server[36].  
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2.2.6 Datasets curation and database generation 
PH-PIPs binding data was curated through text mining of all abstracts published on PubMed. 
First, all abstracts were downloaded from PubMed; then all the abstracts were split into single 
sentence; finally, all the sentences include “PH domain”, “Pleckstrin homology domain”, “bind” 
and “bound” were extracted and saved for the following analysis. All the extracted sentences 
were manually checked and put into a database include the following information: Protein name, 
PIP binding affinity, reference, PubMed ID of the literature and annotation.  
 
2.2.7 Classification of PIP binding using convolutional neural network 
A convolutional neural network is a feed-forward artificial neural network which has been 
widely used in identifying patterns and classifying images. We used Keras and python3 to build 
deep neural network models. And our final model was comprised of two layers of convolution 
layers and two layers of maxpooling layers. The detailed description of the model setting was 
described in Table 2.1.  
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2.3 Results 
2.3.1 PH domain genes were overrepresented in multiple pathways 
Among all the 313 PH domain genes, only 105 genes were annotated in David KEGG pathways. 
Consistent with previous reports, the Ras signaling pathway, actin cytoskeleton, phagocytosis, 
and chemokine signaling pathways were the most significantly overrepresented pathways among 
PH domain genes. Interestingly, the most significant overrepresented pathway was endocytosis, 
which has not been reported widely. Also, immune system pathways such as B cell and T cell 
receptor signaling pathways were also overrepresented among these PH domain genes (Figure 
2.1). Visualization of the pathways reveals that these genes are also significantly involved in the 
protein metabolism, the small molecule transportation, and the cell cycle pathways (Figure 2.2). 
These discoveries suggested future research directions for PH domain proteins, such as small 
molecule transportation and immune functions.  
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Figure 2.1 KEGG pathway analysis of PH domain proteins 
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Figure 2.2 Visualization of overrepresented signaling pathways
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2.3.2 A 20-gene signature resulted in five clusters of clinical samples across 13 cancer types 
To further investigate the expression levels of these genes across different cancer types, we 
downloaded the mRNA expression level and mutation data of 13 types of cancer from 
https://www.synapse.org. Unsupervised hierarchical clustering of the clinical samples based on 
expressional levels of all 313 PH domain genes (PHGs) did not reveal obvious distribution 
patterns (Figure 2.3). Next, we selected the top 20 PHGs with the largest standard deviation 
(SD) to perform the clustering analysis again, which resulted in five main clusters (Figure 2.4). 
Interestingly, KIF1A, CADPS, PLEKHN1, STAP1 and MCF2 were upregulated in Cluster 1; 
GRB14, DOK5, STAP1, RASAL1, and MCF2 were upregulated in Cluster2, which was 
comprised by Colon adenocarcinoma (COAD) samples; CADPS, STAP1, and MCF2 were 
upregulated in Cluster 4, which mainly consists of Heck and Neck Squamous Cell Carcinoma 
(HNSC) and Glioblastoma (GBM); CADS, PLEKHN1, CNKSR2, MCF2, RTKN2, DOK2, and 
RASGRF1 were upregulated in Cluster 5, which was mainly comprised of Kidney Renal Clear 
Cell Carcinoma (KIRC). 
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Figure 2.3 Clustering of clinical samples across 13 most common cancer types based on 
expression level of all 313 PH domain proteins.  
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Figure 2.4 Clustering of clinical samples across 13 most common cancer types based on 
Top20 most differentiated expressed PHGs.  
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2.3.3 Tiam1 is one of the most frequently mutated PH domain genes across 13 cancer types.   
 Next, we wanted to investigate the mutation status of the PH domain proteins across the 13 
cancer types. Only non-silent mutations were considered in the analysis. To this end, we first 
annotated genetic alterations to these genes. Whole exome sequencing identified 12768 non-
silent coding mutations. Uterine Corpus Endometrial Cancer, Lung Squamous Cell Carcinoma 
and Lung adenocarcinoma have the highest mutation frequency of all PH domains (Figure 2.5). 
The top 40 most frequently mutated PH domain genes were further used to build a phylogenetic 
tree on the basis of the sequence similarity (Figure 2.6). Consistent with previous reports, AKT1 
was one of the most frequent mutated genes not only among PH domain genes but also among 
whole human genome in different cancer types [37]. Interestingly, we found Tiam1, a Guanine 
nucleotide factor (GEF) specifically activates Rac1, was one of the top 10 most frequently 
mutated genes. It was most frequently mutated in lung adenocarcinoma, uterine corpus 
endometrial cancer as well as head and neck squamous cell carcinoma (Figure 2.7-2.9).  Then 
we asked which PHDGs had the most frequent mutations in PH domains. We extracted all the 
mutations mapped to PH domains and measure the accumulated mutations at each residue on the 
basis of multiple structural sequence alignment (Figure 2.10). Interestingly, Tiam1 was among 
the most frequently mutated PHGs. Other frequently mutated PHGs include AKT1, PLEK, 
SKAP2, APBB1IP, ITK, PLEKHA6, ARHGAP15, RASGRF1, OSBPL8, ARHGAP24, 
DOCK11, AKT3, ARAP1, and ARHGEF7. All the calculated data used to predict OGs and 
TSGs were listed in Table 2.4. 
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Figure 2.5 The number of PHG mutations per patient across 13 major cancer types in the 
TCGA study. As observed in the figure, uterine, colon, bladder, lung, and head and neck cancer 
patients tend to carry more mutations on PHDG. On the contrary, breast, glioblastoma, kidney, 
ovarian, prostate, and leukemia patients rarely carry mutations on PHDG. 
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Figure 2.6 Tiam1 is one of the most frequently mutated gene across 13 cancer types.  
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Figure 2.7 Two of the PHDGs, AKT1 and SOS1, had somatic mutation pattern which 
significantly resembles that of oncogenes (OG, q<0.1). On the other hand, 80 of the PHGs had 
tumor-suppressor-gene-like (TSG-like) pattern.  
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Figure 2.8 Mutation of Tiam1 status across cancer types. 
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Figure 2.9 Gain-of-function (GOF) and loss-of-function (LOF) mutations of Tiam1 gene 
across 13 types of cancers. Uterine cancer had most GOF and LOF mutations. Tiam1 mutations 
in ovarian, kidney, rectal, bladder, head and neck cancers were exclusively GOF while the 
mutations of Tiam1 in breast cancers were all LOF. 
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Figure 2.10 Accumulated mutations in PH domains.  
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2.3.4 Structural analysis reveals conserved residues in PH domains.  
The PH domains have highly conserved secondary structure, although they only share 20-40% 
sequence identity. We would like to explore the structural features of the PH domain proteins 
further and to see if they share any similar properties in common. We performed multiple 
sequence alignment of all PH domain proteins using MutationAligner [38] in cBioPortal web 
server [39]. Interestingly, several conserved residues were observed in the alignment. For 
example, Trp11, Lys14, Arg23, Tyr26 (in the nomenclature of AKT1) were residues highly 
conserved in the alignments of PH domain proteins (Figure 2.11). These conserved residues 
were mapped to the AKT1 structure in Figure 2.12 Detailed multiple sequence alignment of all 
PH domain proteins annotated in TCGA was presented in Figure 2.13.  
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Figure 2.11 Multiple sequence alignment of PH domain proteins. 
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Figure 2.12 Conserved residues of PH domain mapped to AKT PH domain crystal 
structure.  
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Figure 2.13 Multiple sequence alignment of all PH domain proteins annotated in TCGA.  
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2.3.5 Clustering of the available PH domain proteins.  
Due to the difficulties of crystallization, structures of most PH domain proteins have not been 
determined so far. Structures of PH-PIPs protein complexes were even rarer in the PDB 
database. We collected all the available structures of PH domain proteins (duplicate proteins 
were removed) and performed cluster analysis based on their structure-based sequence alignment 
(Figure 2.14). Interestingly, GRK2, TAPP1, DAPP1, PDPK1, ARNO, GRP1, FAPP1, PEPP1, 
4F7H were clustered in close groups and all of these proteins bound to PIPs.  However, these 
proteins do not seem to have similar functions.  
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Figure 2.14 Clustering of all Crystal structure of PH domain proteins.  
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2.3.6 A heatmap of PIPs binding specificity based on published data 
Due to the limited availability of PH domain protein structures, we collected published PH-PIPs 
binding data [40] and generated a heatmap of the PIPs binding affinity of 95 PH domain proteins 
(Figure 2.15). Interestingly, we found that proteins which bind to PI3P also bind to PI4P and 
PI5P. Moreover, these proteins prefer binding to PI(3,5)P2, but not other types of PIPs. In other 
words, PI(3,5)P2 has similar binding patterns similar to that of PI3P, PI4P, and PI5P. In contrast, 
proteins which bind to PI(3,4,5)P3 more likely bind to PI(4,5)P2 and PI(4,5)P2. These data 
considerably raised our interest to explore the PIPs binding selectivity among all the PH domain 
proteins.  
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Figure 2.15 A heatmap of PIPs binding specificity.  
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2.3.7 Collecting PH-PIPs binding data from PubMed using text mining and building a 
classification model based on Convolutional neural network (CNN). 
As described in the previous section, we downloaded all abstracts published in PubMed and 
extracted all sentences containing PIPs binding information of PH domain proteins. All binding 
information, along with binding affinity (if available), PubMed ID were used to build a database 
for the easy access later on. A part of the database was shown in Figure 2.16.  
 
With the data collected, we built CNN based classification models to predict the binding ability 
of the 313 PH domain proteins. In total, eight models with prediction accuracy larger than 80% 
were generated. Then these models were applied to predict the other proteins on the list. The 
proteins predicted to bind to PIPs were listed in Table 2.3 in descending of confidence. 41 out of 
44 PH domain proteins that found to bind to PIPs were correctly predicted (sensitivity = 
93.18%); and the absence of binding for 47 out of 49 PH domain proteins was correctly 
predicted (specificity = 95.92%). Confusion matrix which showed the prediction result was 
shown in Figure 2.17. ROC curve was plotted and the AUC is 0.98, indicating reliable 
prediction performance of our model.  All these data are available in our web server and a 
snapshot of the webs server was shown as Figure 2.18. 
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Figure 2.16 A snapshot of the database containing PH domain and their PIPs binding 
information.  
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Figure 2.17 Confusion matrix and ROC curve of the model with best prediction ability.  
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Figure 2.18 Display of the webserver for PH domain proteins.  
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Table 2.1 All 313 PH domain proteins.  
 
Protein 
ID 
Gene ID Protein 
ID 
Gene ID Protein 
ID 
Gene 
ID 
Protein 
ID 
Gene ID 
Q12979 
ABR 
Q99490 
CENTG1 
V9HWC8 
HEL-S-
308 
Q6ZR37 
PLEKHG7 
Q15027 ACAP1 Q4ZG22 CENTG2 V9HW03 
HEL-S-
81p Q9ULM0 PLEKHH1 
Q15057 ACAP2 Q96P47 CENTG3 
Q8WWN
9 IPCEF1 Q8IVE3 PLEKHH2 
Q96P50 ACAP3 O14578 CIT Q6DN90 IQSEC1 Q7Z736 PLEKHH3 
O75689 ADAP1 G9CGD6 
CNK3/IPC
EF1 Q5JU85 IQSEC2 K7EIZ3 PLEKHJ1 
Q9NPF8 ADAP2 Q969H4 CNKSR1 P35568 IRS1 Q9Y4G2 PLEKHM1 
P25098 ADRBK1 Q8WXI2 CNKSR2 Q96RG5 IRS2 Q8IWE5 PLEKHM2 
P35626 ADRBK2 Q9Y5P4 COL4A3BP O14654 IRS4 Q6ZWE6 PLEKHM3 
Q8N556 AFAP1 Q15438 CYTH1 Q08881 ITK Q494U1 PLEKHN1 
Q8TED9 AFAP1L1 Q99418 CYTH2 Q15811 ITSN1 Q53GL0 PLEKHO1 
Q8N4X5 AFAP1L2 O43739 CYTH3 Q9NZM3 ITSN2 Q8TD55 PLEKHO2 
E7EUN2 AGAP1 Q9UIA0 CYTH4 J3QSW6 KALRN Q5SXH7 PLEKHS1 
Q8TF27 AGAP11 Q5VWQ8 DAB2IP Q53R16 
KIAA005
3 Q8TCU6 PREX1 
Q99490 AGAP2 Q9UN19 DAPP1 Q5W9H1 
KIAA014
2 Q70Z35 PREX2 
35 
 
Q96P47 AGAP3 Q53RS3 DDEF2 Q5W9G0 
KIAA063
8 F8WBA3 PRKD1 
Q96P64 AGAP4 Q8TDY4 DDEFL1 Q12756 KIF1A Q9BZL6 PRKD2 
A6NIR3 AGAP5 Q9H4E7 DEF6 O60333 KIF1B O94806 PRKD3 
Q5VW22 AGAP6 Q16760 DGKD Q4R9M9 
KIF1Bbet
a A5PKW4 PSD 
Q5VUJ5 AGAP7P Q86XP1 DGKH P10911 MCF2 Q9BQI7 PSD2 
Q5VTM2 AGAP9 Q5KSL6 DGKK O15068 MCF2L Q9NYI0 PSD3 
Q12802 AKAP13 Q658P8 
DKFZp313
N0632 Q86YR7 MCF2L2 Q8NDX1 PSD4 
P31749 AKT1 Q9NTG0 
DKFZp434
G2016 B9EGI2 MPRIP Q5JS13 RALGPS1 
P31751 AKT2 Q9UFY1 
DKFZp434
N101 U6FSN9 
Mprip-
Ntrk1 Q86X27 RALGPS2 
Q9Y243 AKT3 Q5HYM3 
DKFZp686
C0249 
A0A0A0
MQX1 MYO10 C9K0J5 RAPH1 
Q9NQW6 ANLN Q5HYD7 
DKFZp686
K101 Q7Z628 NET1 P20936 RASA1 
Q7Z5R6 APBB1IP Q5HYB0 
DKFZp686
P1738 Q8N5V2 NGEF Q15283 RASA2 
Q9UKG1 APPL1 Q9H3X2 
DKFZp761
E2216 A6NGQ3 OBSCN Q14644 RASA3 
36 
 
Q8NEU8 APPL2 Q69YP8 
DKFZp762
A083 O60890 OPHN1 O43374 RASA4 
Q96P48 ARAP1 Q05193 DNM1 P22059 OSBP C9J798 RASA4B 
Q8WZ64 ARAP2 P50570 DNM2 Q969R2 OSBP2 O95294 RASAL1 
Q8WWN8 ARAP3 Q9UQ16 DNM3 Q9BXB5 OSBPL10 Q9UJF2 RASAL2 
A1A4S6 ARHGAP10 Q96BY6 DOCK10 Q9BXB4 OSBPL11 Q13972 RASGRF1 
Q8IWW6 ARHGAP12 A6NIW2 DOCK11 Q9BXW6 OSBPL1A O14827 RASGRF2 
Q53QZ3 ARHGAP15 
A0A0A0MS
Y4 DOCK9 Q9H4L5 OSBPL3 Q13464 ROCK1 
Q9P2F6 ARHGAP20 Q99704 DOK1 Q9H0X9 OSBPL5 O75116 ROCK2 
Q5T5U3 ARHGAP21 O60496 DOK2 Q9BZF3 OSBPL6 Q9BST9 RTKN 
Q7Z5H3 ARHGAP22 Q7L591 DOK3 Q9BZF2 OSBPL7 Q8IZC4 RTKN2 
Q9P227 ARHGAP23 H3BQ19 DOK4 Q9BZF1 OSBPL8 O95248 SBF1 
Q8N264 ARHGAP24 Q9P104 DOK5 B1AKJ6 OSBPL9 Q86WG5 SBF2 
P42331 ARHGAP25 Q6PKX4 DOK6 Q8WV24 PHLDA1 B7Z5R3 SCAP2 
Q9UNA1 ARHGAP26 Q18PE1 DOK7 Q53GA4 PHLDA2 Q9NRF2 SH2B 
Q6ZUM4 ARHGAP27 Q54A15 DTGCU2 Q9Y5J5 PHLDA3 Q9NRF2 SH2B1 
A6NI28 ARHGAP42 Q92556 ELMO1 Q86UU1 PHLDB1 O14492 SH2B2 
J3KPQ4 ARHGAP9 Q96JJ3 ELMO2 Q86SQ0 PHLDB2 Q9UQQ2 SH2B3 
M0QZR4 ARHGEF1 F8W9E7 ELMO3 Q6NSJ2 PHLDB3 P78314 SH3BP2 
O15085 ARHGEF11 Q8IYI6 EXOC8 O60346 PHLPP1 Q86WV1 SKAP1 
Q9NZN5 ARHGEF12 Q8N4B1 FAM109A P51178 PLCD1 O75563 SKAP2 
Q5VV41 ARHGEF16 Q6ICB4 FAM109B Q8N3E9 PLCD3 Q13424 SNTA1 
37 
 
Q6ZSZ5 ARHGEF18 Q96TA1 FAM129B C9JEA7 PLCD4 Q13884 SNTB1 
Q8IW93 
ARHGEF19 Q86XR2 FAM129C Q4LE43 PLCG1 Q13425 SNTB2 
V9GYM8 ARHGEF2 C9JME2 FARP1 P16885 PLCG2 Q9NSN8 SNTG1 
Q86VW2 ARHGEF25 O94887 FARP2 Q4KWH8 PLCH1 Q07889 SOS1 
Q96DR7 ARHGEF26 Q9BQL6 FERMT1 O75038 PLCH2 Q07890 SOS2 
Q8N1W1 ARHGEF28 Q96AC1 FERMT2 Q15111 PLCL1 Q96N96 SPATA13 
E9PG37 ARHGEF3 Q86UX7 FERMT3 Q9UPR0 PLCL2 P11277 SPTB 
Q8N4T4 ARHGEF39 P98174 FGD1 Q13393 PLD1 P11277 SPTBN1 
E7EV07 ARHGEF4 Q7Z6J4 FGD2 O14939 PLD2 O15020 SPTBN2 
Q8TER5 ARHGEF40 Q5JSP0 FGD3 P08567 PLEK Q9H254 SPTBN4 
Q12774 ARHGEF5 F8VWL3 FGD4 Q9NYT0 PLEK2 Q9NRC6 SPTBN5 
Q15052 ARHGEF6 Q6ZNL6 FGD5 Q9HB21 PLEKHA1 Q9ULZ2 STAP1 
Q14155 ARHGEF7 Q6ZV73 FGD6 Q9HB19 PLEKHA2 Q9UH65 SWAP70 
O43307 ARHGEF9 Q9NXY1 FLJ00004 Q9HB20 PLEKHA3 Q96PV0 SYNGAP1 
Q9ULH1 ASAP1 Q6ZMK7 FLJ00312 Q9H4M7 PLEKHA4 Q9BYX2 TBC1D2 
O43150 ASAP2 Q6ZMJ9 FLJ00357 Q9HAU0 PLEKHA5 B9A6J8 TBC1D2B 
Q8TDY4 ASAP3 Q86YU9 FLJ00414 Q9Y2H5 PLEKHA6 P42680 TEC 
Q86XR2 BCNP1 D3DS14 FLJ10357 E9PKC0 PLEKHA7 Q13009 TIAM1 
P11274 BCR Q13480 GAB1 J3KQS5 PLEKHA8 Q8IVF5 TIAM2 
A2RQD7 BCR-ABL1 Q9UQC2 GAB2 Q9UF11 PLEKHB1 O75962 TRIO 
A9UF07 BCR/ABL Q8WWW8 GAB3 B7WPA5 PLEKHB2 Q9H2D6 TRIOBP 
P51813 BMX Q2WGN9 GAB4 Q96AC1 PLEKHC1 P15498 VAV1 
Q9ULZ2 BRDG1 Q13322 GRB10 A6NEE1 PLEKHD1 P52735 VAV2 
38 
 
Q06187 BTK Q14449 GRB14 Q96S99 PLEKHF1 Q9UKW4 VAV3 
A0A024R8
72 C9orf88 Q14451 GRB7 Q9H8W4 PLEKHF2 Q14D04 VEPH1 
Q9ULU8 CADPS P25098 GRK2 Q9ULL1 PLEKHG1 
 
 
A0A087X1
P3 CADPS2 P35626 GRK3 Q9H7P9 PLEKHG2   
Q5VT25 CDC42BPA D3DWE7 
hCG_1994
053 A1L390 PLEKHG3   
Q9Y5S2 CDC42BPB D3DU33 
hCG_2002
091 Q58EX7 PLEKHG4   
Q6DT37 CDC42BPG D3DSB1 
hCG_2013
210 
A0A1B0G
W72 
PLEKHG4
B   
C9J126 CDH2 
A0A024RB
A8 
hCG_2015
932 O94827 PLEKHG5   
Q2V6Q1 CENTA2 D6W646 
hCG_2225
3 
Q3KR16 
PLEKHG6   
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Table 2.2 Parameters of Convolutional neural network.  
 
Layer (type)                 Output Shape              Parameter # 
================================================================= 
embedding_1 (Embedding)      (None, 330, 8)            184 
_________________________________________________________________ 
conv1d_1 (Conv1D)            (None, 330, 32)           1568 
_________________________________________________________________ 
max_pooling1d_1 (MaxPooling1 (None, 165, 32)           0 
_________________________________________________________________ 
conv1d_2 (Conv1D)            (None, 165, 32)           3104 
_________________________________________________________________ 
max_pooling1d_2 (MaxPooling1 (None, 82, 32)            0 
_________________________________________________________________ 
flatten_1 (Flatten)          (None, 2624)              0 
_________________________________________________________________ 
dense_1 (Dense)              (None, 128)               336000 
_________________________________________________________________ 
dense_2 (Dense)              (None, 2)                 258 
================================================================= 
Total parameters: 341,114 
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Table 2.3 Proteins predicted to bind to PIPs.  
Q9NRF2 B7Z5R3  O60333  Q12756  Q54A15  Q7Z736  
P35626 B9A6J8  O60346  Q12774  Q58EX7  Q86SQ0  
P11277 B9EGI2  O60496  Q12802  Q5HYB0  Q86UU1  
Q96AC1 C9J126  O60890  Q13009  Q5HYD7  Q86UX7  
Q86XR2 C9J798  O75038  Q13322  Q5HYM3  Q86VW2  
Q96TA1 C9JEA7  O75116  Q13393  Q5JS13  Q86WG5  
DDEFL1 C9JME2  O75563  Q13424  Q5JSP0  Q86WV1  
Q9HAU0 C9K0J5  O75689  Q13425  Q5JU85  Q86X27  
Q99490 D3DS14  O75962  Q13464  Q5KSL6  Q86XP1  
A0A024RBA8  D3DSB1  O94806  Q13480  Q5SXH7  Q86XR2  
A0A024RBK8  D3DU33  O94827  Q13884  Q5T5U3  Q86YR7  
 Q9ULZ2 D3DWE7  O94887  Q13972  Q5VT25  Q86YU9  
Q01082 D6W646  O95248  Q14155  Q5VTM2  Q8IVE3  
Q6DN90 E7EUN2  P08567  Q14449  Q5VUJ5  Q8IVF5  
Q96P64 E7EV07  P10911  Q14451  Q5VV41  Q8IW93  
Q86UW7 E9PG37  P11274  Q14644  Q5VW22  Q8IWE5  
Q96P47 E9PKC0  P15498  Q14D04  Q5VWQ8  Q8IWW6  
Q9HD67 F8VWL3  P16885  Q15027  Q5W9G0  Q8IYI6  
Q15283 F8W9E7  P20936  Q15052  Q5W9H1  Q8IZC4  
Q9BZ29 F8WBA3  P22059  Q15057  Q658P8  Q8N1W1  
 O43307 G9CGD6  P25098  Q15111  Q69YP8   
 P25098 H3BQ19  P31749  Q15438  Q6DT37   
Q9Y2H5 J3KPQ4  P31751  Q15811  Q6ICB4   
Q96PX9 J3KQS5  P35568  Q16760  Q6NSJ2   
Q12979 J3QSW6  P35626  Q18PE1  Q6PKX4   
Q6ZR37 K7EIZ3  P42331  Q2V6Q1  Q6ZMJ9   
A1A4S6  M0QZR4  P42680  Q2WGN9  Q6ZMK7   
A1L390  O14492  P50570  Q3KR16  Q6ZNL6   
A2RQD7  O14578  P51178  Q494U1  Q6ZSZ5   
A5PKW4  O14654  P51813  Q4KWH8  Q6ZUM4   
A6NEE1  O14827  P52735  Q4LE43  Q6ZV73   
A6NGQ3  O14939  P78314  Q4R9M9  Q6ZWE6   
A6NI28  O15020  P98174  Q4ZG22  Q70Z35   
A6NIR3  O15068  Q05193  Q53GA4  Q7L591   
A6NIW2  O15085  Q06187  Q53GL0  Q7Z5H3   
A9UF07  O43150  Q07889  Q53QZ3  Q7Z5R6   
B1AKJ6  O43374  Q07890  Q53R16  Q7Z628   
B7WPA5  O43739  Q08881  Q53RS3  Q7Z6J4   
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Table 2.4 Annotations of mutations among all 313 PH domain proteins.  
CDS 
n_
m
ut 
n_
clu
st 
n_
O
G 
n_mut
_in_clu
st 
min_cl
ustersi
ze 
corr_fa
ctor_O
G 
n_T
SG 
n_TSG_
nonsen
se 
corr_fa
ctor_TS
G 
n_si
l 
OG_
scor
e 
TSG
_sco
re 
OG_
p 
log_
OG_
p 
TSG
_p 
log_
TSG
_p 
DG
_p 
log_
DG_
p 
OG
_q 
TSG
_q 
DG_
q  
AKT1 
14
43 43 1 43 20 NA 
0.85
583
4 0 0 0 0 
0.45
945
9 0 
3.08
E-44 
-
100
.18
9 1 0 
3.08
E-44 
-
100
.18
9 
8.22
E-
42 1 
8.22
E-
42 
RAS
A1 
31
44 89 0 56 0 NA 
0.29
859
5 33 21 
0.93
100
7 0 0 
0.37
349
4 1 0 
1.34
E-21 
-
48.
062
7 
1.34
E-21 
-
48.
062
7 1 
3.57
E-
19 
3.57
E-
19 
ROC
K1 
40
65 
10
5 0 69 0 NA 
0.33
514
2 36 13 
0.86
029
2 0 0 
0.34
444
4 1 0 
2.20
E-20 
-
45.
265
5 
2.20
E-20 
-
45.
265
5 1 
2.93
E-
18 
2.93
E-
18 
ARA
P3 
46
35 
10
1 0 66 0 NA 0 35 7 
0.56
309
4 0 0 
0.35
087
7 1 0 
7.46
E-14 
-
30.
226
3 
7.46
E-14 
-
30.
226
3 1 
6.64
E-
12 
6.64
E-
12 
ROC
K2 
41
67 65 0 43 0 NA 
0.24
957
8 22 7 
0.77
985
1 0 0 
0.33
333
3 1 0 
1.42
E-11 
-
24.
980
1 
1.42
E-11 
-
24.
980
1 1 
9.46
E-
10 
9.46
E-
10 
DOC
K11 
62
22 
11
6 0 87 0 NA 
0.20
356
3 29 20 
0.66
943
1 0 0 
0.24
359 1 0 
4.08
E-10 
-
21.
619
8 
4.08
E-10 
-
21.
619
8 1 
2.03
E-
08 
2.03
E-
08 
ITSN
2 
50
94 81 0 59 0 NA 
0.16
590
6 22 10 
0.76
313
4 0 0 
0.27
419
4 1 0 
4.56
E-10 
-
21.
508
3 
4.56
E-10 
-
21.
508
3 1 
2.03
E-
08 
2.03
E-
08 
ARA
P2 
51
15 95 0 70 0 NA 0 25 14 
0.66
551
9 0 0 
0.26
984
1 1 0 
6.00
E-10 
-
21.
233
9 
6.00
E-10 
-
21.
233
9 1 
2.29
E-
08 
2.29
E-
08 
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MCF
2 
27
78 90 4 68 2 NA 
0.34
421
5 22 14 
0.76
218
3 0 
0.04
347
8 
0.24
637
7 
0.03
259
8 
-
3.4
235 
2.78
E-09 
-
19.
701
5 
9.06
E-11 
-
23.
125 1 
9.27
E-
08 
9.27
E-
08 
TRIO 
92
94 
14
5 0 110 0 NA 0 35 12 
0.41
809
2 0 0 
0.24
590
2 1 0 
2.42
E-08 
-
17.
537
8 
2.42
E-08 
-
17.
537
8 1 
6.85
E-
07 
6.85
E-
07 
MCF
2L2 
33
45 90 0 70 0 NA 
0.31
682
9 20 15 
0.77
686
6 0 0 
0.22
857
1 1 0 
2.57
E-08 
-
17.
477
9 
2.57
E-08 
-
17.
477
9 1 
6.85
E-
07 
6.85
E-
07 
PSD3 
31
44 68 0 47 0 NA 
0.06
773
8 21 6 
0.56
716
4 0 0 
0.30
769
2 1 0 
3.96
E-08 
-
17.
045
6 
3.96
E-08 
-
17.
045
6 1 
9.60
E-
07 
9.60
E-
07 
DAB
2IP 
31
98 42 0 24 0 NA 0 18 4 
0.48
507
5 0 0 0.45 1 0 
4.38
E-08 
-
16.
943
9 
4.38
E-08 
-
16.
943
9 1 
9.74
E-
07 
9.74
E-
07 
IRS4 
37
74 
11
5 0 85 0 NA 0 30 9 
0.38
495 0 0 
0.27
272
7 1 0 
1.75
E-07 
-
15.
556
2 
1.75
E-07 
-
15.
556
2 1 
3.60
E-
06 
3.60
E-
06 
MYO
10 
61
77 99 0 69 0 NA 0 30 15 
0.37
853
8 0 0 
0.29
729
7 1 0 
2.16
E-07 
-
15.
346
4 
2.16
E-07 
-
15.
346
4 1 
4.13
E-
06 
4.13
E-
06 
PLEK
HA5 
33
51 58 0 42 0 NA 
0.15
687
9 16 5 
0.65
671
6 0 0 
0.28
947
4 1 0 
2.93
E-07 
-
15.
043
5 
2.93
E-07 
-
15.
043
5 1 
5.21
E-
06 
5.21
E-
06 
OSB
PL11 
22
44 38 0 26 0 NA 
0.46
811
4 12 8 
0.82
835
8 0 0 
0.32
258
1 1 0 
3.28
E-07 
-
14.
931 
3.28
E-07 
-
14.
931 1 
5.47
E-
06 
5.47
E-
06 
43 
 
APPL
1 
21
30 36 0 24 0 NA 
0.30
140
3 12 4 
0.72
537
3 0 0 
0.34
615
4 1 0 
6.48
E-07 
-
14.
249
8 
6.48
E-07 
-
14.
249
8 1 
1.02
E-
05 
1.02
E-
05 
ARH
GEF6 
23
31 66 0 51 0 NA 
0.34
701
5 15 11 
0.79
566
5 0 0 
0.22
641
5 1 0 
1.56
E-06 
-
13.
370
1 
1.56
E-06 
-
13.
370
1 1 
2.32
E-
05 
2.32
E-
05 
SYN
GAP
1 
40
32 61 0 40 0 NA 0 21 9 
0.39
582
1 0 0 
0.33
333
3 1 0 
3.81
E-06 
-
12.
477
5 
3.81
E-06 
-
12.
477
5 1 
5.36
E-
05 
5.36
E-
05 
ARH
GAP
12 
25
41 52 0 39 0 NA 
0.26
865
7 13 11 
0.76
705
8 0 0 0.25 1 0 
4.43
E-06 
-
12.
327 
4.43
E-06 
-
12.
327 1 
5.81
E-
05 
5.81
E-
05 
RAS
A2 
25
50 48 0 34 0 NA 
0.15
451
6 14 4 
0.66
992 0 0 
0.28
125 1 0 
4.63
E-06 
-
12.
283
9 
4.63
E-06 
-
12.
283
9 1 
5.81
E-
05 
5.81
E-
05 
GAB
1 
21
75 40 0 25 0 NA 
0.08
059
7 15 0 
0.46
055
4 0 0 
0.38
888
9 1 0 
4.79
E-06 
-
12.
249
8 
4.79
E-06 
-
12.
249
8 1 
5.81
E-
05 
5.81
E-
05 
ARH
GAP
21 
58
74 98 0 78 0 NA 
0.13
879
2 20 10 
0.59
950
2 0 0 
0.20
339 1 0 
5.18
E-06 
-
12.
169
8 
5.18
E-06 
-
12.
169
8 1 
6.02
E-
05 
6.02
E-
05 
SKAP
1 
10
80 23 0 13 0 NA 
0.15
614
2 10 7 
0.57
089
6 0 0 
0.46
153
8 1 0 
7.19
E-06 
-
11.
843
3 
7.19
E-06 
-
11.
843
3 1 
8.00
E-
05 
8.00
E-
05 
ITSN
1 
51
66 
10
2 0 71 0 NA 0 31 8 
0.25
401
8 0 0 
0.30
769
2 1 0 
7.51
E-06 
-
11.
799
3 
7.51
E-06 
-
11.
799
3 1 
8.02
E-
05 
8.02
E-
05 
44 
 
SNT
G1 
15
54 82 0 64 0 NA 
0.18
625
2 18 7 
0.53
242
4 0 0 
0.22
727
3 1 0 
1.11
E-05 
-
11.
406
5 
1.11
E-05 
-
11.
406
5 1 
0.00
011
4 
0.00
011
4 
CNK
SR1 
21
42 30 0 20 0 NA 
0.01
169
8 10 4 
0.71
393 0 0 
0.33
333
3 1 0 
1.56
E-05 
-
11.
065
2 
1.56
E-05 
-
11.
065
2 1 
0.00
015
5 
0.00
015
5 
PHLP
P1 
51
54 48 0 35 0 NA 
0.12
348
4 13 8 
0.62
888
3 0 0 
0.26
666
7 1 0 
2.42
E-05 
-
10.
628
8 
2.42
E-05 
-
10.
628
8 1 
0.00
023
1 
0.00
023
1 
ARH
GAP
27 
16
47 29 0 18 0 NA 0 11 4 
0.56
309
4 0 0 
0.37
5 1 0 
3.01
E-05 
-
10.
411
8 
3.01
E-05 
-
10.
411
8 1 
0.00
027
7 
0.00
027
7 
OSB
PL1A 
28
53 48 0 36 0 NA 0 12 2 
0.66
625
2 0 0 0.25 1 0 
4.04
E-05 
-
10.
117
6 
4.04
E-05 
-
10.
117
6 1 
0.00
035
9 
0.00
035
9 
GRB
14 
16
23 40 0 28 0 NA 0 12 3 
0.61
094
5 0 0 
0.29
166
7 1 0 
4.17
E-05 
-
10.
085
4 
4.17
E-05 
-
10.
085
4 1 
0.00
035
9 
0.00
035
9 
SOS1 
40
02 86 1 77 4 NA 
0.55
803
7 9 5 
0.79
975
1 0 
0.04
651
2 
0.10
144
9 
5.60
E-05 
-
9.7
902 
0.02
5353 
-
3.6
748
5 
1.42
E-06 
-
13.
465
1 
0.00
747
6 
0.08
461
7 
0.00
063
3 
PLEK
HA3 
90
3 17 0 10 0 NA 0 7 4 
0.69
104
5 0 0 
0.41
666
7 1 0 
7.98
E-05 
-
9.4
364
2 
7.98
E-05 
-
9.4
364
2 1 
0.00
066
6 
0.00
066
6 
RAP
H1 
37
53 43 0 32 0 NA 0 11 3 
0.64
111
3 0 0 0.25 1 0 
0.00
0123 
-
9.0
030
3 
0.00
012
3 
-
9.0
030
3 1 
0.00
099
5 
0.00
099
5 
45 
 
CNK
SR2 
31
05 77 0 64 0 NA 
0.35
159
3 13 5 
0.66
451
8 0 0 
0.17
647
1 1 0 
0.00
0244 
-
8.3
173
4 
0.00
024
4 
-
8.3
173
4 1 
0.00
191
8 
0.00
191
8 
PLEK
HM3 
22
86 24 0 16 0 NA 0 8 7 
0.61
380
6 0 0 
0.33
333
3 1 0 
0.00
0272 
-
8.2
093 
0.00
027
2 
-
8.2
093 1 
0.00
207
6 
0.00
207
6 
VAV
3 
25
44 71 0 59 0 NA 
0.23
685
9 12 6 
0.73
300
2 0 0 
0.17
307
7 1 0 
0.00
0284 
-
8.1
65 
0.00
028
4 
-
8.1
65 1 
0.00
211 
0.00
211 
PSD 
30
75 57 0 45 0 NA 
0.02
992
8 12 5 
0.56
059
7 0 0 
0.21
875 1 0 
0.00
0302 
-
8.1
054
5 
0.00
030
2 
-
8.1
054
5 1 
0.00
217
9 
0.00
217
9 
FARP
2 
31
65 47 0 32 0 NA 0 15 4 
0.33
059
7 0 0 
0.31
25 1 0 
0.00
0382 
-
7.8
697
6 
0.00
038
2 
-
7.8
697
6 1 
0.00
268
5 
0.00
268
5 
PLEK
HA6 
31
47 61 0 50 0 NA 
0.17
429 11 2 
0.73
880
6 0 0 
0.17
777
8 1 0 
0.00
0509 
-
7.5
828
9 
0.00
050
9 
-
7.5
828
9 1 
0.00
348
5 
0.00
348
5 
TRIO
BP 
70
98 
11
4 0 95 0 NA 
0.00
647
7 19 10 
0.49
899
2 0 0 
0.15
789
5 1 0 
0.00
0576 
-
7.4
590
2 
0.00
057
6 
-
7.4
590
2 1 
0.00
384
6 
0.00
384
6 
OSB
PL6 
28
17 62 0 50 0 NA 
0.14
629
2 12 3 
0.59
771
5 0 0 
0.18
918
9 1 0 
0.00
0769 
-
7.1
707
8 
0.00
076
9 
-
7.1
707
8 1 
0.00
500
6 
0.00
500
6 
ACA
P2 
23
37 44 0 35 0 NA 
0.21
715
4 9 6 
0.63
764
5 0 0 
0.21
428
6 1 0 
0.00
0917 
-
6.9
938
7 
0.00
091
7 
-
6.9
938
7 1 
0.00
583
3 
0.00
583
3 
PREX
2 
48
21 
13
0 0 109 0 NA 
0.07
168
2 21 9 
0.38
104
9 0 0 0.16 1 0 
0.00
1053 
-
6.8
0.00
105
3 
-
6.8 1 
0.00
653
9 
0.00
653
9 
46 
 
559
7 
559
7 
PLEK
HA7 
33
66 45 0 34 0 NA 0 11 3 
0.45
074
6 0 0 0.25 1 0 
0.00
1179 
-
6.7
431
6 
0.00
117
9 
-
6.7
431
6 1 
0.00
698
6 
0.00
698
6 
SWA
P70 
17
58 23 0 17 0 NA 
0.12
238
8 6 0 
0.85
956
6 0 0 0.25 1 0 
0.00
1179 
-
6.7
431
6 
0.00
117
9 
-
6.7
431
6 1 
0.00
698
6 
0.00
698
6 
CDC
42BP
A 
51
60 93 0 78 0 NA 
0.07
099
6 15 10 
0.54
551
2 0 0 
0.15
686
3 1 0 
0.00
1204 
-
6.7
224 
0.00
120
4 
-
6.7
224 1 
0.00
698
6 
0.00
698
6 
ARH
GEF1
2 
46
35 66 0 54 0 NA 
0.14
189
1 12 8 
0.46
055
4 0 0 0.2 1 0 
0.00
1346 
-
6.6
106
6 
0.00
134
6 
-
6.6
106
6 1 
0.00
764
6 
0.00
764
6 
ARH
GAP
10 
23
61 45 0 34 0 NA 
0.03
634
8 11 3 
0.46
600
3 0 0 
0.23
809
5 1 0 
0.00
1494 
-
6.5
061
7 
0.00
149
4 
-
6.5
061
7 1 
0.00
831
1 
0.00
831
1 
RTK
N2 
18
30 40 0 32 0 NA 0 8 6 
0.77
415
6 0 0 
0.19
354
8 1 0 
0.00
161 
-
6.4
313
7 
0.00
161 
-
6.4
313
7 1 
0.00
85 
0.00
85 
TEC 
18
96 41 0 32 0 NA 
0.33
033
6 8 4 
0.74
913
9 0 0 
0.19
354
8 1 0 
0.00
161 
-
6.4
313
7 
0.00
161 
-
6.4
313
7 1 
0.00
85 
0.00
85 
OSB
PL3 
26
64 50 0 36 0 NA 0 14 2 
0.26
194 0 0 
0.30
769
2 1 0 
0.00
1624 
-
6.4
231
1 
0.00
162
4 
-
6.4
231
1 1 
0.00
85 
0.00
85 
SBF1 
56
04 71 0 56 0 NA 0 15 1 
0.30
751
4 0 0 
0.22
727
3 1 0 
0.00
1867 
-
6.2
832
5 
0.00
186
7 
-
6.2
832
5 1 
0.00
958
8 
0.00
958
8 
47 
 
PLEK
HH2 
44
82 95 0 81 0 NA 0 14 9 
0.57
432
8 0 0 
0.14
545
5 1 0 
0.00
1985 
-
6.2
221
8 
0.00
198
5 
-
6.2
221
8 1 
0.00
999
9 
0.00
999
9 
ARH
GEF2
5 
17
43 22 0 16 0 NA 0 6 2 
0.67
388
1 0 0 
0.26
666
7 1 0 
0.00
2898 
-
5.8
436
8 
0.00
289
8 
-
5.8
436
8 1 
0.01
433 
0.01
433 
DNM
2 
26
13 37 0 27 0 NA 0 10 5 
0.43
262
9 0 0 0.25 1 0 
0.00
3737 
-
5.5
895
2 
0.00
373
7 
-
5.5
895
2 1 
0.01
786
9 
0.01
786
9 
AKA
P13 
84
54 
12
0 0 105 0 NA 
0.17
443
5 15 6 
0.61
795
9 0 0 
0.12
162
2 1 0 
0.00
3748 
-
5.5
865
7 
0.00
374
8 
-
5.5
865
7 1 
0.01
786
9 
0.01
786
9 
SPTB
N1 
70
95 
11
3 0 95 0 NA 0 18 14 
0.25
019
6 0 0 
0.17
857
1 1 0 
0.00
5657 
-
5.1
748
3 
0.00
565
7 
-
5.1
748
3 1 
0.02
649
9 
0.02
649
9 
DGK
D 
36
45 69 0 53 0 NA 0 16 7 
0.26
194 0 0 
0.22
222
2 1 0 
0.00
5876 
-
5.1
368
1 
0.00
587
6 
-
5.1
368
1 1 
0.02
659
3 
0.02
659
3 
PLEK
HH3 
23
82 28 0 22 0 NA 
0.50
417
4 6 2 
0.65
671
6 0 0 
0.22
222
2 1 0 
0.00
5876 
-
5.1
368
1 
0.00
587
6 
-
5.1
368
1 1 
0.02
659
3 
0.02
659
3 
VEP
H1 
25
02 73 0 62 0 NA 0 11 0 
0.56
136 0 0 
0.14
634
1 1 0 
0.00
6886 
-
4.9
782
4 
0.00
688
6 
-
4.9
782
4 1 
0.03
064
3 
0.03
064
3 
PLCL
1 
29
94 
12
2 0 107 0 NA 
0.10
211
3 15 13 
0.55
659
2 0 0 
0.11
764
7 1 0 
0.00
747 
-
4.8
968 
0.00
747 
-
4.8
968 1 
0.03
269
9 
0.03
269
9 
48 
 
ANL
N 
33
75 51 0 40 0 NA 
0.18
739
6 11 5 
0.39
925
4 0 0 0.2 1 0 
0.00
8704 
-
4.7
439
3 
0.00
870
4 
-
4.7
439
3 1 
0.03
631
3 
0.03
631
3 
DNM
3 
25
92 54 0 44 0 NA 
0.26
229
7 10 5 
0.37
779
9 0 0 0.2 1 0 
0.00
8704 
-
4.7
439
3 
0.00
870
4 
-
4.7
439
3 1 
0.03
631
3 
0.03
631
3 
FGD
4 
23
01 31 0 24 0 NA 0 7 3 
0.63
955
2 0 0 0.2 1 0 
0.00
8704 
-
4.7
439
3 
0.00
870
4 
-
4.7
439
3 1 
0.03
631
3 
0.03
631
3 
FGD
6 
42
93 71 0 62 0 NA 
0.50
096
6 9 6 
0.66
815
9 0 0 
0.12
766 1 0 
0.01
3302 
-
4.3
198
1 
0.01
330
2 
-
4.3
198
1 1 
0.05
464
2 
0.05
464
2 
ARH
GEF1
9 
24
09 26 0 20 0 NA 
0.13
959
6 6 3 
0.50
959
5 0 0 
0.23
076
9 1 0 
0.01
5331 
-
4.1
778
5 
0.01
533
1 
-
4.1
778
5 1 
0.06
019
8 
0.06
019
8 
PLEK
HG1 
41
58 69 0 51 0 NA 0 18 6 
0.18
860
2 0 0 
0.23
076
9 1 0 
0.01
5331 
-
4.1
778
5 
0.01
533
1 
-
4.1
778
5 1 
0.06
019
8 
0.06
019
8 
RTK
N 
16
92 23 0 18 0 NA 0 5 1 
0.57
089
6 0 0 
0.23
076
9 1 0 
0.01
5331 
-
4.1
778
5 
0.01
533
1 
-
4.1
778
5 1 
0.06
019
8 
0.06
019
8 
CYT
H3 
12
00 21 0 13 0 NA 0 8 2 
0.24
477
6 0 0 0.4 1 0 
0.01
6126 
-
4.1
272
9 
0.01
612
6 
-
4.1
272
9 1 
0.06
158
8 
0.06
158
8 
PHL
DB2 
37
14 80 2 70 0 NA 
0.29
515
5 10 6 
0.60
640
8 0 0 
0.12
244
9 1 0 
0.01
6147 
-
4.1
260
4 
0.01
614
7 
-
4.1
260
4 1 
0.06
158
8 
0.06
158
8 
49 
 
FGD
1 
28
86 61 0 49 0 NA 0 12 0 
0.22
761
2 0 0 
0.21
428
6 1 0 
0.01
8913 
-
3.9
678
9 
0.01
891
3 
-
3.9
678
9 1 
0.07
013
7 
0.07
013
7 
PLEK
HA8 
13
68 20 0 15 0 NA 
0.02
487
6 5 1 
0.68
700
6 0 0 
0.21
428
6 1 0 
0.01
8913 
-
3.9
678
9 
0.01
891
3 
-
3.9
678
9 1 
0.07
013
7 
0.07
013
7 
RAS
AL2 
38
10 72 0 64 0 NA 
0.23
268
9 8 5 
0.71
091
9 0 0 
0.11
764
7 1 0 
0.01
9385 
-
3.9
432
7 
0.01
938
5 
-
3.9
432
7 1 
0.07
09 
0.07
09 
ARH
GAP
20 
35
76 79 0 68 0 NA 
0.03
026
3 11 4 
0.48
507
5 0 0 
0.13
157
9 1 0 
0.02
0482 
-
3.8
882
1 
0.02
048
2 
-
3.8
882
1 1 
0.07
291
6 
0.07
291
6 
CDH
2 
27
21 94 0 82 0 NA 
0.23
172 12 10 
0.40
497
5 0 0 
0.13
157
9 1 0 
0.02
0482 
-
3.8
882
1 
0.02
048
2 
-
3.8
882
1 1 
0.07
291
6 
0.07
291
6 
PLCG
2 
37
98 82 0 68 0 NA 0 14 6 
0.31
343
3 0 0 
0.15
384
6 1 0 
0.02
202 
-
3.8
157
8 
0.02
202 
-
3.8
157
8 1 
0.07
736
1 
0.07
736
1 
SPTB
N5 
11
02
5 84 0 74 0 NA 
0.01
094
5 10 2 
0.47
014
9 0 0 
0.12
820
5 1 0 
0.02
2705 
-
3.7
851
6 
0.02
270
5 
-
3.7
851
6 1 
0.07
844
7 
0.07
844
7 
OPH
N1 
24
09 51 0 41 0 NA 0 10 3 
0.28
891
3 0 0 0.2 1 0 
0.02
2917 
-
3.7
758
8 
0.02
291
7 
-
3.7
758
8 1 
0.07
844
7 
0.07
844
7 
PLEK
HA2 
12
78 17 0 10 0 NA 0 7 2 
0.35
634
3 0 0 
0.33
333
3 1 0 
0.02
3521 
-
3.7
498
4 
0.02
352
1 
-
3.7
498
4 1 
0.07
949
6 
0.07
949
6 
50 
 
AKT3 
14
40 40 0 33 0 NA 
0.13
854 6 5 
0.72
537
3 0 0 
0.13
793
1 1 0 
0.03
1701 
-
3.4
514 
0.03
170
1 
-
3.4
514 1 
0.10
231
7 
0.10
231
7 
ARH
GEF5 
47
94 38 0 28 0 NA 0 10 6 
0.17
993
4 0 0 
0.28
571
4 1 0 
0.03
2024 
-
3.4
412
8 
0.03
202
4 
-
3.4
412
8 1 
0.10
231
7 
0.10
231
7 
ARH
GEF7 
23
49 67 0 57 0 NA 
0.01
410
1 10 4 
0.25
213
2 0 0 
0.17
647
1 1 0 
0.03
219 
-
3.4
361
1 
0.03
219 
-
3.4
361
1 1 
0.10
231
7 
0.10
231
7 
CDC
42BP
B 
51
36 58 0 46 0 NA 0 12 5 
0.28
768
7 0 0 
0.17
647
1 1 0 
0.03
219 
-
3.4
361
1 
0.03
219 
-
3.4
361
1 1 
0.10
231
7 
0.10
231
7 
APPL
2 
19
95 43 0 37 0 NA 
0.39
054
7 6 5 
0.71
393 0 0 
0.12
903
2 1 0 
0.03
9339 
-
3.2
355
4 
0.03
933
9 
-
3.2
355
4 1 
0.12
357
1 
0.12
357
1 
DGK
K 
33
54 50 0 37 0 NA 0 13 2 
0.16
324
6 0 0 0.25 1 0 
0.04
1527 
-
3.1
814
1 
0.04
152
7 
-
3.1
814
1 1 
0.12
892
7 
0.12
892
7 
ARH
GEF1 
27
84 51 0 41 0 NA 
0.15
164
2 9 1 
0.37
779
9 0 0 
0.15
789
5 1 0 
0.04
3125 
-
3.1
436
5 
0.04
312
5 
-
3.1
436
5 1 
0.13
084
5 
0.13
084
5 
ASA
P2 
30
21 46 0 38 0 NA 0 8 2 
0.40
705
6 0 0 
0.15
789
5 1 0 
0.04
3125 
-
3.1
436
5 
0.04
312
5 
-
3.1
436
5 1 
0.13
084
5 
0.13
084
5 
ABR 
25
80 47 0 35 0 NA 0 12 2 
0.18
140
1 0 0 
0.22
222
2 1 0 
0.05
1933 
-
2.9
577
9 
0.05
193
3 
-
2.9
577
9 1 
0.15
58 
0.15
58 
51 
 
CAD
PS2 
38
91 73 0 61 0 NA 0 12 7 
0.28
768
7 0 0 
0.14
285
7 1 0 
0.05
5665 
-
2.8
883
9 
0.05
566
5 
-
2.8
883
9 1 
0.16
514
1 
0.16
514
1 
CAD
PS 
39
45 
10
8 0 98 0 NA 
0.06
193
5 10 7 
0.46
112
5 0 0 0.1 1 0 
0.05
7568 
-
2.8
547
9 
0.05
756
8 
-
2.8
547
9 1 
0.16
707
3 
0.16
707
3 
KALR
N 
89
61 
17
7 0 158 0 NA 0 19 14 
0.28
109
5 0 0 0.1 1 0 
0.05
7568 
-
2.8
547
9 
0.05
756
8 
-
2.8
547
9 1 
0.16
707
3 
0.16
707
3 
PRK
D1 
27
39 87 0 78 0 NA 
0.19
509 9 6 
0.40
878
9 0 0 
0.11
111
1 1 0 
0.06
2605 
-
2.7
709
1 
0.06
260
5 
-
2.7
709
1 1 
0.17
563
6 
0.17
563
6 
ARH
GAP
24 
22
47 28 0 22 0 NA 0 6 5 
0.36
247
3 0 0 0.2 1 0 
0.06
315 
-
2.7
622
4 
0.06
315 
-
2.7
622
4 1 
0.17
563
6 
0.17
563
6 
ARH
GAP
9 
22
53 38 0 32 0 NA 
0.16
417
9 6 6 
0.25
621
9 0 0 0.2 1 0 
0.06
315 
-
2.7
622
4 
0.06
315 
-
2.7
622
4 1 
0.17
563
6 
0.17
563
6 
SH2
B3 
17
28 12 0 9 0 NA 
0.38
413
2 3 0 
0.81
275
4 0 0 0.2 1 0 
0.06
315 
-
2.7
622
4 
0.06
315 
-
2.7
622
4 1 
0.17
563
6 
0.17
563
6 
ARH
GEF9 
15
45 39 0 34 0 NA 
0.34
130
7 5 2 
0.58
315
6 0 0 
0.13
043
5 1 0 
0.06
973 
-
2.6
631
3 
0.06
973 
-
2.6
631
3 1 
0.18
997
9 
0.18
997
9 
SH2
B1 
20
52 37 0 32 0 NA 0 5 4 
0.62
349
5 0 0 
0.13
043
5 1 0 
0.06
973 
-
2.6
631
3 
0.06
973 
-
2.6
631
3 1 
0.18
997
9 
0.18
997
9 
52 
 
PLEK
HG6 
23
73 23 0 19 0 NA 0 4 2 
0.48
507
5 0 0 
0.18
181
8 1 0 
0.07
5091 
-
2.5
890
6 
0.07
509
1 
-
2.5
890
6 1 
0.20
251
8 
0.20
251
8 
ARH
GAP
15 
14
28 41 0 36 0 NA 
0.11
924
2 5 3 
0.59
950
2 0 0 0.12 1 0 
0.08
5218 
-
2.4
625
4 
0.08
521
8 
-
2.4
625
4 1 
0.22
753
3 
0.22
753
3 
ADR
BK2 
20
67 41 0 35 0 NA 0 6 2 
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0.56
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-
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0.11
111
1 1 0 
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-
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-
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6 1 
0.63
239
1 
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0.31
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-
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3 0 0 
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-
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-
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2.4 Discussion 
Although PH domain proteins have been studied for more than 20 years, lots of information 
about these proteins are still illusive. In this chapter, our genomics analysis identified a list of 
most frequently mutated PHGs and most up-regulated PHGs. Among these genes, AKT1 was the 
one with most attention and best studied in the past decades. Other than AKT1, we identified a 
list of interesting genes such as CNKSR2, DOCK, KIF1A, and CADPS. Of these genes, Tiam1 
was one of the most interesting genes. Analysis of 13 types of most common cancer dataset 
revealed that Tiam1 was one of the top10 most frequently mutated genes. Interestingly, when it 
considered PH domain only, Tiam1 was also one of the most frequently mutated genes. 
However, it did not show significant difference of mutation frequency among these 13 cancer 
types. The expression level of Tiam1 only significantly increased in neuroendocrine prostate 
cancer patients, but not any other types of cancers. This makes Tiam1 a very interesting drug 
target in this type of cancer. Through structural multiple sequence alignment, several conserved 
residues, such as arginine and tryptophan, involved in PIPs binding and recognition were 
identified. These conserved residues provide precious information to identify the binding pocket 
of PIPs especially in proteins without PH-PIPs complex crystal structures.  
 
Then we collected all the PH domain proteins with crystal structures and tried to identify the 
residues which were responsible for the PIPs binding specificity. However, no clear cluster was 
obtained due to the limit of the crystal structure numbers. So we collected all PH-PIPs binding 
information from PubMed and saved it as a database. Using these information, we built a CNN 
based machine learning model to predict their PIPs binding ability. The visualization of the 
protein clusters and PIPs binding specificities were displayed in the webserver. To our 
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knowledge, for the first time, PH-PIPs binding data were displayed and published in a websever. 
This may bring significant convenience to the community to utilize the data.  
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Chapter 3: In silico discovery of small molecule inhibitors targeting Tiam1 
3.1 Introduction 
As the most frequently mutated gene in all types of human cancers [41], Ras has received 
unprecedented attention of developing inhibitors in the past three decades[42]. Despite numerous 
efforts and strategies, such as disruption of localization of the protein and synthetic lethality, have 
been intensively attempted, it is still not even close to effectively inhibit aberrant Ras pathways 
[43]. Recently, direct targeting Ras has been intensively studied and some groups have identified 
compounds bind to Ras proteins directly [44, 45]. Nevertheless, animal experiments of these 
compounds are still unavailable at this moment. As a consequence, efforts switched to target the 
downstream pathways of Ras including the Raf-MEK-ERK pathway and PI3K-AKT pathway, and 
it has achieved some success. Recently, inhibitors targeting Ral, another Ras-like GTPase which 
is a downstream pathways of Ras, were developed [46].  
 
Herein, we focus on Tiam1, another downstream pathway of Ras. Tiam1 was characterized as an 
effector of Ras in 2002 [47], which is responsible for the activation of another Ras-like GTPase, 
Rac1 [48, 49]. It was reported that Rac1 activation is required for Ras transformation [50]. Rac1 
is known to be involved in a lot of normal cell physiological processes including actin dynamics, 
cell trafficking, cell growth and cell motility [51, 52]. Recently, aberrant activation of Rac1 has 
been associated with cancer cell migration [53]. The activation of Rac1 requires GEF to catalyze 
the reactions of GDP release and allows GTP binding. Tiam1 is one of these GEFs responsible for 
Rac1 activation. Interestingly, Tiam1 has also been found overexpressed in multiple cancers, 
contributing to cancer cell migration [54, 55]. All these evidence suggests that Tiam1 is a 
promising target for cancer treatment, especially cancer metastasis. However, this pathway has not 
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been effectively targeted yet. To date, there is not any small-molecule compound reported to 
directly bind to Tiam1 and the known Rac1 inhibitors can only produce limited inhibition activity 
with IC50 around 50µM [56]. Another strategy is to inhibit Rac1-Tiam1 protein-protein interaction, 
which shows better efficacy in inhibiting Rac-GTPase level in cancer cells with best IC50 of 2.5 
µM [57]. Herein, we propose a novel approach to inhibit Tiam1 using small-molecule inhibitors 
targeting cPH domain of the Tiam1 protein. It has been shown that Phosphatidylinositol phosphate 
(PIP) activates Tiam1 through binding to cPH domain [58]. Loss of this binding prevents Rac1 
activation in vivo [59]. Different from other PH domains, cPH domain of Tiam1 is not responsible 
for the membrane binding function, but critical for Rac1 activation, given the evidence that 
mutation of cPH domain abolishes the activation of Rac1 while the membrane association is 
maintained [59]. Another characteristic of this PH domain is that two loops exist between β1/ β2 
and β3/ β4 strands, which are not observed in other PH domains. A big but flexible pocket was 
formed between these two loops in the cPH domain which provide the opportunity for binding of 
compounds.  
 
We hypothesized that PIP competitive inhibitors may exhibit pharmacology through inhibition of 
Rac1. However, the binding site of PIP in cPH domain is unknown. In this study, we conducted a 
comprehensive analysis of all PH-PIP bound structures available in PDB to predict the putative 
binding site of PIP in this PH domain. Through our in-house integrated platform, herein we 
reported two series of compounds, to our knowledge, which are the first inhibitors directly bind to 
Tiam1with strong affinity. These compounds have shown selective inhibition of prostate cell 
proliferation, invasion, and migration.  
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Figure 3.1 Workflow of in silico screen process.  
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3.2 Methods and materials 
3.2.1 Sequence alignment and sequence logo generation 
All PH-PIPs structure complexes available in PDB (Table 5.1) were collected to perform multiple 
sequence alignment based on their secondary structures using STRAP [35].  The output of the 
alignment was then used to generate the signatures of conserved residues involved in PIP binding 
using Weblogo web server[36].  
 
3.2.2 Ensemble docking 
In order to explore the structural flexibility of Tiam1 cPH, a 6-ns molecular dynamics simulation 
was performed on cPH domain of human Tiam1 and snapshots were saved every 10ps. The 
snapshots were clustered based on single linkage algorithm with a cutoff of 0.1nm using Gromacs 
5.0.6. As a result, 10 clusters were generated and one representative structure in each cluster of 
snapshots was chosen for the ensemble docking study. The variation of these selected structures 
was analyzed through comparison of their mutual RMSD values. The snapshots showed the good 
diversity and reasonably represent the conformational variation of the cPH domain of Tiam1.  
 
3.2.3 Chemical dataset and virtual screening 
A collection of 10 million compounds was curated from various sources such as Maybridge, 
Chembridge, and PubChem. The chemical structures were processed and washed using MOE 
software[60]. In this process, hydrogens were added and the protonation state of ionizable groups 
were calculated. Then compound structures were passed to energy minimization using the default 
setting in the MOE software. GOLD was utilized to perform in silico screening using our curated 
library described above through our high performing computing cluster based on the identified 
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pocket mentioned above. In the molecular docking studies, residues within 6Å of the PIP and 
small-molecule putative binding pocket were set as flexible. The binding conformations were 
ranked according to their Gold Scores. A protein structural pharmacophore model was generated 
using GRID v22c[61] as indicated in our previous publication [31]. Grid calculation was 
performed within a box containing the docking site with 1Å beyond each dimension. In this 
process, the GRID directive Move was defined as 1 (MOVE=1) in order to allow the flexibility of 
the side chains. The molecular interaction fields were calculated in order to define the interaction 
between the protein receptor and three types of probes including hydrogen bond donors, 
hydrophobic probes, and hydrogen bond receptors. The derived pharmacophores defined by these 
binding features were used to evaluate the 5,000 hits with the best scores in the screening. The 
compounds fit in the pharmacophore would be selected to perform cluster analysis using MACCS 
fingerprints on the basis of the Tanimoto coefficient. The compound with highest docking score 
in each cluster was selected and the docking pose was individually selected according to the 
molecular visualization.  
 
3.2.4 Pharmacophore Modeling 
A ligand-based pharmacophore was generated using the MOE program from the active 
molecules (KD values) tested based on the enzymatic analysis.  
 
3.2.5 Surface plasmon resonance (SPR) assays.   
Binding affinity of Tiam1 cPH domain with compounds were tested using Biacore 2000. Data 
analysis was performed using BIAevaluation v4.1 and Biacore 2000 control software. Detailed 
information was described in reference [30]. 
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3.2.6 Culture of prostate cancer and normal prostate cell lines.   
Human prostate cancer cell lines (PC3 and DU145) and normal prostate cell lines (RWPE-1) were 
obtained from the American Type Culture Collection (ATCC). Cells were cultured in DMEM 
medium with 10% fetal bovine serum. Compounds were dissolved and stored in DMSO.  
 
3.2.7 Rac1 activation assay.   
Rac1 activity in cells were measured using G-LISA activation assays kit (Cytoskeleton, Inc, Denver, 
Co). Prostate cancer cells were cultured until almost confluence, followed by starving for 48 
hours. After treatment with compounds for 4 hours, cells were harvested and tested Rac1 activity 
according to the protocol.  
 
3.2.8 Wound healing assay.   
PC-3 and DU145 cells were cultured in six-well plates. Once the cells formed a monolayer, a 
wound was made from the middle of each well in the plate. Cells were then incubated with different 
concentration of compounds or DMSO for 18 hours. The wound closure speed was measured by 
calculating the width of the gap before and after treatment of the compounds.  
 
3.2.9 Lamellipodia formation assay.   
Cells were plated in the tissue plates at a concentration of 3000 cells/well and were cultured for 12 
hours. After starving for 48 hours, cells were incubated with TPH3 for 12 hours.  Then the 
coverslips were removed and cells were fixed with paraformaldehyde (3.7% dissolved in PBS) for 
10 minutes. Then cells were stained with phalloidin- rhodamine in PBS.  After mounting using 
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ProLong Gold, cells were visualized using 40X microscope and pictures were analyzed using 
imaging software.  
 
3.2.10 Colony formation assay.   
Prostate cancer cells were plated in 6-well plates and cultured for 24 hours. Then cells were treated 
with compounds at concentrations of 10 or 20 µM. Media was replaced twice a week and 
compounds were added. After 12 days, colonies were stained with crystal violet [62]. Then the 
number of colonies were counted using the ColCount software.  
 
3.2.11 Matrigel invasion assay.   
Prostate cancer cells were incubated with a compound or DMSO for 4 hours. Then cells were 
cultured on an upper chamber on which pre-coated with Matrigel. The bottom well were filled 
with complete media using as chemoattractants. After 24 hours, invading cells were stained using 
crystal violet and counted at 10 random fields.   
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Table 3.1. Structures used in structural multiple sequence alignment. 
PDB ID Protein name 
1FAO Cytohesin-3 
1FHW GRP1 
1FOE Tiam1 
1MAI Phospholipase C  
1UPR PEPP1 
1UNQ AKT1 
1U27 Cytohesin-2 
1W1D PDK1 
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3.3 Results 
3.3.1 Structural analysis of cPH domain of Tiam1 protein.   
Structure of the cPH domain of the Tiam1 protein was retrieved from PDB (PDB ID: 1FOE). 
Similar to other PH domains, cPH domain of Tiam1 contains seven beta sheets and a c-terminal 
alpha helix, which are typical components of PH domains. However, a close look of this crystal 
structure reveals unique characteristics. The loops between β1 and β2 (loop β1/β2), β3 and β4 
strands (loop β3/β4) are much longer than other PH domains with crystal structures available. 
According to the mutagenesis analysis performed by other groups, this big loop is involved in the 
binding with PI3P and PI5P. It is also reported that mutations of lysines to Glutamines on this loop 
disrupt the binding of PI3P and PI5P to the Tiam1 cPH domain and significantly impair Rac1 
activation in cell lines [59]. The existence of this big loop indicates high structural flexibility, 
which significantly increases the difficulty to identify the active site of PIP and small molecules. 
In order to take into account of structural flexibility of this domain, a 6-ns molecular dynamics 
simulation was performed on the apo structure of Tiam1 cPH domain using GROMACS. 
According to our experience, 6-ns MD simulation has the best performance of generating structure 
ensembles for docking studies. Root mean square fluctuations of C-alpha Atoms of residues reveal 
that residues from 50-70 have the highest fluctuations (Figure 3.2). Not surprisingly, these 
residues comprise the huge loop of cPH domain of Tiam1, which contributes to the binding of 
PI3P and PI5P. In order to obtain most of the possible conformations of this flexible domain, 
snapshots were taken every 10ps during the simulation and in total 600 snapshots were generated. 
To get the most diverse structures for following ensemble docking study, cluster analysis was then 
performed using GROMACS cluster package. This analysis produced 10 clusters of structures and 
a representative frame of each cluster was selected for our following ensemble docking study. The 
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superimposed structures of these ten snapshots were shown in Figure 3.3. In order to make sure 
these snapshots are diverse and can represent the snapshots, RMSD between every two structures 
were calculated. It was shown that these values range from 1-4, which indicated these clusters 
represent a good diversity of the c-terminal PH domain of the Tiam1 protein (Figure 3.4). The 
variation of RMSD value in each cluster is reasonable which renders the good quality of our 
clustering.  
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Figure 3.2 Root mean square fluctuations of C-alpha Atoms of residues in Tiam1 protein. It 
shows that residues from 50-70 have the highest fluctuations, which is consistent of the long loop 
in ther C terminal.  
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Figure 3.3. Selected snapshots from MD simulation for ensemble docking study.  
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Figure 3.4. RMSDs between each pair of structures.  
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3.3.2 Characterization of PIP binding site in cPH domain of Tiam1.  
Although cPH domain does not involve in the process of Tiam1 protein translocation and 
structurally slightly different from other typical PH domains, PI3P and PI5P have been shown to 
bind to this domain and play critical roles in the regulation of Tiam1 activity. Also, loss of PIP 
binding was shown to impair the Rac1 activation in vivo [58, 59]. Although crystal structures of 
Tiam1 cPH domain have been determined, there is no PIP or drug-like compound bound Tiam1 
protein complex solved at this point. Determination of the PIP and PIPs binding site is a critical 
step in order to rationally develop inhibitors to impair Tiam1 activity. According to the mutation 
analysis, loop β1/β2 and loop β3/β4 are involved in the interaction with PI3P and PI5P. However, 
the PIP is relative small compound while the loops are too large to pinpoint the PIP accurate 
binding site. Therefore, we collected all PH-PIP complexes in PDB and performed multiple 
sequence alignment based on their secondary structures using software STRAP. In order to identify 
the conserved residue for PIP binding, the sequence logos of the PH-PIP complex were generated 
based on alignment results using Weblogo3 (Figure 3.5). Interestingly, we found several invariant 
residues located on the two loops including Lysines, Arginines, and Tryptophans that were 
involved in the direct interaction between PIPs and PH domain. These residues provide positively 
charged interface, which is favorable for the binding of a phosphate group. Since cPH of Tiam1 
selectively bind to PI3P and PI5P, we then selected all PIPs-PH complexes containing 3-
phosphoinositide and 5-phosphoinositide for another structural alignment. We found three 
residues, Lys-1286, Tyr1304, Arg-1330 (In the nomenclature of 1FOE) are strictly conserved and 
these residues contribute to direct interaction with PIPs (Figure 2B). Of the nine PH-PIPs domain 
complexes, eight proteins have a lysine and an arginine in the consistent positions. Actually, we 
visualized the structure of the protein (1UPR) which does not have lysine in the alignment, there 
82 
 
is a lysine in the PIPs binding pocket and forms direct interaction with one of the phosphate groups. 
As a result, our docking site was defined as the center of Lys1286, Tyr1304 and Arg1330 with a 
radius of 10Å, which covered the putative binding sites of all ten selected structures. Electrostatic 
potential surface maps of cPH domain reveal positive charge around the putative binding pocket 
(Figure 3.6). In order to further characterize residues critical for ligand binding, the binding site 
of Tiam1 cPH domain was investigated with GRID. For GRID calculation, a grid box was 
constructed to enclose the target with 1Å beyond each dimension; molecular interaction fields 
(MIFs) were calculated with three types of probes: hydrophobic residues, nitrogen atoms 
(hydrogen bond acceptor), and water molecules (hydrogen bond donor). Local energy minima 
were derived for these three MIFs so that the corresponding residues could be identified to analyze 
the interactions between the protein and the small-molecule ligands. The PIP compound comprises 
of a long hydrophobic acyl tail and a flexible inositol phosphate group. Taking into account that 
the flexibility and hydrophobicity of the long acyl tail may decrease the accuracy of docking and 
simulation, we only use the PIP head group, rather than full-length PIP, in our current docking and 
simulation studies. Ensemble docking was performed against this putative binding site using 
maximal searching efficiency and all conformations were kept for visualization. Then MD 
simulations were performed on selected binding poses to refine the protein-ligand complex 
structures. All the PIP-PH complexes bind stably during the simulations. Poses selection are based 
on these criteria: ability of PIP to bind to lipid tail and attach to the cell membrane; interaction 
with the conserved basic residues; docking score. The best binding poses with high GOLD docking 
scores are shown in Figure 3.7. Interestingly, in our study, PI3P and PI5P have very similar 
docking score. The Gold Scores of PI3P and PI5P are 60.62 and 62.38 respectively. Moreover, 
both of these compounds share very similar docking poses. It seems the 5-phosphate group tends 
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to flip to the 3-phosphate position in order to acquire lower energy and more stable binding mode. 
In this way, both of PI3P and PI5P form hydrogen bonds with Tyr1304 and Arg1330. However, 
for both PI3P and PI5P, each phosphate can only form one hydrogen bond in our best-scored 
conformations. In this study, we also included PI(4,5)P, a compound showed very weak binding 
in experimental results, as a negative control of our docking studies. Interestingly, in our docking 
process, PI(4,5)P was not able to dock into the pocket with reasonable conformations based on our 
criteria. One possibility is that the 4-phosphate group position was not able to form polar 
interactions with the receptor due to the large space in that area. All these observations were highly 
in agreement with the experimental results that binding affinity of PI3P and PI5P (~20µM) are 
much weaker compared to PIPs with more than one phosphate group (10nM~590nM), reflecting 
the accuracy of our docking study.   
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Figure 3.5 Structural sequence alignment of Tiam1 protein crystal structures.  
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Figure 3.6 Electrostatic potential surface maps of Tiam1 cPH domain reveal positive 
charge around the putative binding pocket.  
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Figure 3.7. Predicted PI3P and PI5P binding poses with best docking scores.  
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3.3.3 In silico discovery of inhibitors of Tiam1 binding to cPH domain.  
Aiming to identify small-molecule compounds fitting into the binding pocket of PI3P and PI5P, 
our in-house chemical database containing ten million commercially available compounds were 
screened using the GOLD software. Moreover, a protein structure pharmacophore was generated 
as a filter of the virtual screening hits (Figure 3.8). Residue R1330, K1284, K1286, K1287, K1305, 
were selected as residues in favor of interacting with hydrogen bond acceptors; Residue D1306 is 
identified as a hydrogen donor; Residues W1285, W1326, Y1304, F1331 form hydrophobic probes 
which prefer to interact with hydrophobic moieties. Considering the possible false positive result 
caused by pain compounds, the docking results were then filtered using our in-house platform for 
pain compound prediction.  The top 5000 hits were then further performed cluster analysis on the 
basis of their chemical diversity. 203 clusters of compounds were generated and the hits with 
highest docking scores in each cluster was chosen and performed another docking experiment with 
flexible residues in the binding pocket and maximum searching efficiency. The 100 hits with 
highest docking scores were manually visualized to analyze their interaction in the docking results. 
Finally, we selected 22 top-ranked compounds to test their binding affinity and inhibition activity 
of Rac1 in vitro. ADMET properties were calculated using MOE software as described in the 
Methods and materials section. Seven out of the selected 22 compounds were found to bind to 
Tiam1 cPH domain (KD<50µM) using SPR binding assays. Compounds TPH3 (KD = 0.73 ± 0.1 
μM, IC50 = 5.9 ± 0.1 μM) (Figure 3.10) (Figure 3.11), TPH3 (KD = 2.7±0.2 μM, IC50= 2.38 ± 
0.98 μM) were two identified hits with strong binding affinity to Tiam1 cPH domain and potent 
inhibition of Rac1 (Figure 3.9). Subsequently, these two compounds were treated with PC-3 
prostate cancer cell line for 4 hours at concentrations ranging from 1 µM to 20 µM. Then Rac1 
activities of these cells were detected using G-LISA Kit BK128. TPH3 significantly decreased the 
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Rac1-GTP binding in a dose-dependent manner, indicating inhibition of the cellular activity of 
Rac1 (Figure 3.12). At the concentration of 10 µM, TPH3 exhibited as much as 40% inhibition of 
Rac1 activation in cells and the IC50 value of this compound was 2.38 ± 0.98 μM. Interestingly, 
TPH3 showed relative stronger binding affinity while weaker inhibition of Rac1 in cells. 
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Figure 3.8.  A structure-based pharmacophore was generated using GRID method as a filter 
of the virtual screening hits. 
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Figure 3.9.  Putative binding site of TPH3 in Tiam1 cPH domain.  
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Figure 3.10 Chemical structures of the hits.  
 
 
 
 
  
(TPH3) (TPH7) 
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Figure 3.11 TPH3 binds to the Tiam1 cPH domain.  
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Figure 3.12 TPH3 inhibits Rac1 activity in cells.  
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3.3.4 TPH3 inhibits prostate cancer cell proliferation and migration. 
Rac1 has been known to be a critical controller of the cell motility through regulating actin cytoskeleton 
in cells. [63].  Lamellipodia is one of most important protein induced by Rac1 [64]. With the 
treatment of 20µM TPH3 for 18 hours, the wound was unable to close in PC3 cells.  (Figure 
3.13) In order to clarify whether the impaired cell motility of PC3 cells were due to lamellipodia 
dysfunction, lamellipodia formation and matrigel cell invasion studies were performed. 
Interestingly, the lamellipodia formation was significantly reduced in the treatment group 
compared with the control group.  (Figure. 3.14). Thus, the reduction of prostate cancer cell 
motility after the treatment of TPH3 may be due to the downregulation of lamellipodia and actin 
disruption. Then we tested the effect of TPH3 in invasion assays using prostate cancer cells.  
Treatment with 20 µM TPH3 reduced the number of invading cells in the lower chambers 
(Figure. 3.15). Finally, TPH3 decreased the colony forming abilities of PC-3, and DU145 at the 
concentration of 20 µM (Figure. 3.16).  In a nutshell, these results demonstrated that TPH3 
reduced the cells capacities to migrate and invade in prostate cancer cell line models.  
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Figure 3.13. TPH3 inhibits wound healing in prostate cancer cell line.  
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Figure 3.14 TPH3 inhibited lamellipodia formation in prostate cancer cells.  
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Figure 3.15 TPH3 inhibits prostate cancer cell invasion in Matrigel invasion assay.  
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Figure 3.16 TPH3 inhibits prostate cancer cell proliferation in colony assay.  
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3.3.6. Complex structure refinement and Prediction of molecular interaction between 
TPH3 and cPH Tiam1.  
At this moment, we are not able to determine the cPH-PIP or cPH-TPH3 complex structures, 
probably due to the high flexibility of the long loops in this domain. In order to obtain more 
detailed insight into the structural basis of binding of our experimentally verified inhibitors with 
Tiam1, we subsequently performed more careful docking studies using GOLD software followed 
by structural refinement using MD simulation to obtain the most stable binding modes. Not 
surprising, the docking score of TPH3 (GOLD Score = 84.48) is significantly higher than TPH3 
(GOLD Score=73.16), and it is consistent with our experimental data in which TPH3 had better 
binding affinity than TPH7. And such consistency also strongly supports the binding modes of our 
inhibitors. Figure 3.17A shows that both TPH3 and TPH7 fit in a similar binding pocket. Trp1285 
forms interaction with a hydrogen in thiophene of TPH3 and Tyr1304 forms H-arene interaction 
with the benzene group of TPH3 (Figure 3.17B). TPH7 has similar interaction with these two 
residues (Figure 3.17C). Especially, both of these two compounds form hydrogen bonds with 
Arg1330, a critical residue involved in binding of PIP with Tiam1 cPH domain. Interestingly, 
TPH3 forms two hydrogen bonds with the receptor while TPH7 can form only one. The better 
binding to this Arg1330 residue may also explain the better binding affinity of TPH3 comparing 
to TPH7.  Based on these active compounds, we generate the pharmacophore of the inhibitors of 
Tiam1 cPH domain. All the inhibitors strongly bind to Tiam1 cPH domain contain two aromatic 
groups and a hydrophobic group which forms interactions with residues around (Figure 3.17C).  
They also receive hydrogen from Arg1330 to form hydrogen bonds.  Together, our model indicates 
how TPH3 and TPH7 interact with Tiam1 cPH domain and critical components of the active 
inhibitors (Figure 3.17D).  
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Figure 3.17 Complex structure refinement and Prediction of molecular interaction between 
TPH3 and cPH Tiam1. 
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3.3.7. Bound ligands induce Tiam1 cPH domain conformational changes and stabilize 
protein complexes.   
In order to investigate the structural changes of cPH induced by our inhibitor, we performed 100ns 
MD simulation on the cPH-TPH3 complex using the selected docking pose as the initial structure. 
The protein-ligand structure bound stably during the simulation. We were surprised to find that 
the alpha helix between β1/ β2 strands moves upward, which is not observed either in the MD 
simulation of apo and PIP bound Tiam1 cPH domain (Figure 3.18). As a result, Trp1285, a residue 
in the alpha helix, moves upward significantly and forms interaction with a hydrogen in thiophene. 
This movement forms a hydrophobic core which favorably interacts with aromatic groups which 
exist both in TPH3 and TPH7.  At the same time, the loop β3/β4 strands move inward and form a 
“closed” conformation. As a consequence, the position of Trp1326 significantly changes and forms 
interaction of the terminal aromatic group of TPH3, which is not seen in TPH7. This may also 
partly explain why TPH3 has better binding affinity than TPH3. Also, Arg1330 is able to move 
inward and forms critical hydrogen bonds with a nitrogen on triazolidine. With the binding of our 
ligands, the orientation of Tyr1304 shifts and forms interaction with the benzene group of the 
compound. Rearrangement of these side chains created a pocket with a favorable interaction 
between the ligand and the protein, which properly explain the binding mechanism of our 
inhibitors. To obtain the mechanical mechanism how our protein-ligand complexes move, we built 
an Anisotropic Network Model (ANM) for normal node analysis on our Tiam1-TPH3/9 complex 
models. The predicted movement of the structure complex is in agreement with our molecular 
dynamics simulation results. Also, principle component analysis (PCA) was also performed on our 
MD simulation snapshots (Figure 3.18).  .  
 
 
102 
 
Figure 3.18 Bound ligands induce Tiam1 cPH domain conformational changes and stabilize 
protein complexes.   
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3.4 Discussion 
Great progress has been made in delineating the relationship between Rac1, Tiam1, and prostate 
cancer metastasis. Over-activation of Rac1 was identified to increase cancer cell motility [53]. 
Therefore, Rac1 has received a lot of attention as a target for cancer therapy. Initially, Gao et al. 
reported a small-molecule compound, NSC23766, which bound to Rac1-GEF interactions. This 
compound inhibited Rac1 activation induced by TrioN in activity with an IC50 of around 50µM. 
Based on the same model, Ruffoni et al subsequently de novo designed a diverse small-molecule 
lead compound that bound to Rac1-Tiam1 protein-protein interaction. The most active compound 
showed Rac1 inhibition with an IC50 of 2.5 µM in smooth muscle cells. All these reported 
compounds were focused on Rac1-GEF protein-protein interactions. In sharp contrast, we use 
another strategy to target cPH domain of Tiam1 in order to achieve better potency and efficacy. 
Another important reason that our interest shifts to developing compounds targeting Tiam1 is that 
upregulated Tiam1 has been also observed in prostate cancer patients and it is highly associated 
with tumor metastasis. Also, Tiam1 was reported to be as an independent overall survival marker 
of prostate cancer patients. Therefore, our compounds may not only contribute as a probe to obtain 
a better understanding of Tiam1 signaling in cancer cells, but also potentially benefit patients with 
aberrant Tiam1 expression levels.  
 
Besides providing a particularly appealing target for cancer metastasis, Tiam1 is also a very 
interesting target as a protein containing two PH domains. The N-terminal PH domain serves as a 
typical function related to protein translocation to the cell membrane, which is similar to other PH 
domains. However, its cPH domain is more related to Rac1 activation and it prefers to bind to the 
PI(5)P instead of PIPs with two or more phosphate groups. The atypical function of cPH domain 
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may be related to its different structure compared to other PH domains. Two long loops are 
observed in this PH domain between β1/β2 and β3/β4 sheets. A big cavity is formed between these 
two big loops and the PIP was known to bind to this cavity. Despite high flexibility caused by 
these loops, we integrated multiple sequence alignment and ensemble docking to identify the 
putative PIP binding site in this cPH domain. Then based on the binding pocket, we identified two 
series of compounds, TPH3 and TPH7, which bound to the receptor in nanomolar or low 
micromolar KD values.  Both of these compounds bind to a very similar position in the pocket and 
shared similar pharmacophore characteristics. Both TPH3 and TPH7 have two hydrophobic 
moieties and form hydrogen bonds with Arg1330 of the receptor. Upon binding to the receptor, 
TPH3 and TPH7 induce conformational changes within the cPH domain. The alpha helix located 
in loop β1/β2 moves upward and the loop β3/β4 moves inward to form a “closed conformation”, 
which enhance the binding of these two compounds.  
 
Although our compounds showed strong binding affinity to the Tiam1 cPH domain and efficient 
inhibition of Rac1 activity, a number of limitations and questions remain. Firstly, the mechanism 
of how PIP is involved in Rac1 activation is unknown. A hypothesis is that the PIP binding changes 
the orientation of the protein around the cell membrane and promotes the Rac1 activation.  And 
the conformational changes induced by our inhibitors may inhibit the structural change in PIP 
binding state and further inactivate Tiam1 and Rac1. Further experiments need to be performed to 
verify these hypotheseses. Another question is that TPH3 has better binding affinity but lower 
inhibition effect compared to TPH7. One possible reason is the permeability of TPH3 to the cell 
membrane is not as good as TPH7. Improvement of the cell membrane permeability will be 
important to get a more potent compound in TPH3 series.  
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In summary, through our integrated computational platform, we successfully identified the first 
Tiam1 inhibitor that binds to its cPH domain and exhibits inhibition of cancer cell progression and 
migration. The compounds efficiently inhibit Rac1 activation induced by Tiam1. Although we 
have identified useful compounds for the purpose of exploring Tiam1 signaling pathways, it is still 
far from the application in the clinic. From the translational perspective, the selectivity of our 
compounds against other PH domains needs to further test; while from the structural perspective, 
optimization of these two leads will focus on increasing the cell membrane permeability of TPH3 
and increasing binding affinity of TPH7.  
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Chapter 4 Summary and future directions 
4.1 Summary of PH domain protein features 
In chapter 2, we have performed comprehensive genomics analysis of PHGs across 13 most 
common cancer types in TCGA dataset. Most frequently mutated PHGs were identified: AKT1, 
AKT2, Tiam1, OBSCN, KALRN, TRIO, PREX2, and PLCL1. AKT1, FAM129B, SPTBN1 and 
Tiam1 are most frequently upregulated genes among all 313 PHGs. PHGs were overrepresented 
in different pathways including endocytosis, Ras signaling pathway, and B/T cell receptor 
signaling pathways. Across all the 13 types of cancers, PH domain proteins have highest 
mutation rates in colon cancer, uterine cancer and lung adenocarcinoma. Interestingly, the 
variety of the mutation numbers in these samples were much higher comparing to other cancer 
types. Of the 313 PHGs, Tiam1 was found to be one of the top10 most frequently mutated genes. 
But the mutation frequency did not show significant difference in different cancer types. Then 
we found that Tiam1 was significantly increased in neuroendocrine prostate cancer, but not other 
molecular type of prostate cancers. Structure multiple sequence alignment revealed conserved 
residues like Arginine and Tryptophan in β1/β2 loop and β3/β4 loop were involved in PIPs 
binding. Within PH domain, the frequency of Tiam1 mutation was also among the top 10 most 
mutated, which makes Tiam1 an interesting target in prostate cancer cell therapy. Also, we 
collected all available PH domain proteins and their PIPs binding selectivity data to build a 
webserver for public availability.  
 
4.2 Summary of small molecule inhibitors targeting Tiam1 
In chapter 3, we identified two potent and selective Tiam1 cPH domain small molecule inhibitors 
using an integrative in silico screening method. Hits were picked from an ensemble docking 
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experiment using 10 diverse snapshots obtained from molecular dynamics. Our molecular 
modeling results showed that the compounds bound to a pocket between loop β1/β2 and loop 
β3/β4. These two compounds showed strong binding affinity to Tiam1 cPH domain and 
inhibition of Rac1 activity in prostate cancer cells. TPH3 also showed inhibition of cancer cell 
proliferation in prostate cancer cell lines. Also, TPH3 inhibited prostate cancer cell migration 
using a wound healing assay. Finally, through ANM and PCA analysis of snapshots obtained 
from molecular dynamics experiments, we found that the Tiam1 intrinsic motility at least 
partially contributes to the binding of the compounds.  
 
4.3 Future directions in small molecule inhibitors targeting Tiam1 
Although our compounds showed promising binding affinity to the Tiam1 and significant 
inhibition of Rac1 activity in cells, more potent compounds are still in need. Continuous study of 
the effect of these two compounds Future direction of computational design of small molecule 
inhibitors may pay more attention on the Arginine and Tryptophan within the binding pocket. 
However, the chemical properties such as ability to penetrate the cells should be considered in 
the process of in silico screen and lead optimization. Polar compounds may help with the binding 
affinity improvement but may be difficult to enter the cells. Another concern is the selectivity to 
other PH domain proteins. As is discussed above, there were around 300 PH domain proteins in 
human proteome and they have very similar secondary structures although with low sequence 
identity. However, the docking programs now available in the market have not shown good 
correlation between the docking scores and actual activity. As a result, new scoring functions 
which can improve the docking accuracy of PH domain proteins are unmet needs.  
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4.3 Future directions in drug discoveries targeting PH domain proteins.  
As discussed above, accurate scoring of docking against PH domains remains a great challenge 
in small molecule inhibitor development in this protein family. So more reliable scoring 
functions need to be developed. PH domain proteins may go to different cellular sub 
localizations such as cytoplasmic membrane, endosome and Golgi apparatus. However, it 
is still not clear that which proteins go to which membrane by binding to which PIPs. So 
annotation of these 313 proteins would be an important step in order to develop small 
inhibitors targeting these proteins. Next is to achieve the selectivity of compounds. One 
method is to use machine learning techniques to build a model to predict PIPs binding 
specificity based on published data.  
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